Joanna F Swain

This inventor holds 12 USPTO granted patents and 5 published patent applications and 2 EPO patents. Top assignee: Bristol-Myers Squibb Compnay. Active years: 2014-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Joanna F Swain. Retrieved from https://idiyas.com/inventor/joanna-f-swain

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 12 (Patent Applications = 5)

% Patents Active = 100.0

EPO Patents = 2 (Patent Applications = 4)

Average Co-Inventor Count = 10.4

ph-index = 8

Forward Citations = 198(Granted Patents)

Company Filing History:

12 out of 3,745

Bristol-Myers Squibb Compnay

patents

Years Active: 2014-2023

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11813315 - Fibronectin based scaffold domain proteins that bind to myostatin (2023-11-14),

2. 10934572 - Serum albumin binding molecules (2021-03-02),

3. 10406212 - Fibronectin based scaffold domain proteins that bind to myostatin (2019-09-10),

4. 10245302 - Fibronectin based scaffold domain proteins that bind to myostatin (2019-04-02),

5. 10221438 - Serum albumin binding molecules (2019-03-05),

6. 9662373 - Fibronectin based scaffold domain proteins that bind to myostatin (2017-05-30),

7. 9540424 - Serum albumin binding molecules (2017-01-10),

8. 9493546 - Fibronectin based scaffold domain proteins that bind to myostatin (2016-11-15),

9. 8993265 - Fibronectin based scaffold domain proteins that bind to myostatin (2015-03-31),

10. 8969289 - Serum albumin binding molecules (2015-03-03),

11. 8933199 - Fibronectin based scaffold domain proteins that bind to myostatin (2015-01-13),

12. 8853154 - Fibronectin based scaffold domain proteins that bind to myostatin (2014-10-07),

Title: The Innovative Contributions of Joanna F. Swain

Introduction

Joanna F. Swain, based in Concord, MA, is a distinguished inventor with a remarkable portfolio of 12 patents. Her groundbreaking work primarily focuses on therapeutic applications aimed at treating various medical conditions, contributing significantly to the fields of biotechnology and medicine.

Latest Patents

Two of her most recent patents highlight her innovative prowess. The first patent, titled "Fibronectin based scaffold domain proteins that bind to myostatin," pertains to fibronectin-based scaffold domain proteins designed to interact with myostatin. This invention holds promise for therapeutic applications in treating serious conditions such as muscular dystrophy, sarcopenia, diabetes, and more. The second patent, "Serum albumin binding molecules," introduces an antibody-like protein based on the tenth fibronectin type III domain (Fn3), which is capable of binding to serum albumin. This patent also discusses fusion molecules combining this Fn3 with other proteins for diagnostic and therapeutic uses.

Career Highlights

Joanna Swain works at Bristol-Myers Squibb Company, a prominent player in the pharmaceutical industry. Throughout her career, she has demonstrated a commitment to innovation, leading to her establishment as a key inventor in her field.

Collaborations

Throughout her career, Joanna has collaborated with notable professionals such as Sharon T. Cload and Linda Engle. These partnerships have fostered an environment of innovation and creativity, further enhancing her contributions to the biotechnology sector.

Conclusion

Joanna F. Swain's contributions to the field of biotechnology through her patented inventions are significant. Her dedication to developing therapeutic solutions for critical health issues exemplifies the essence of innovation in medicine. As she continues to advance her research, her work promises to make a lasting impact on public health.

Profile summary based on public USPTO records.